chartexchange

BLTE
Belite Bio, Inc
stockNASDAQADR

At CloseNov 18, 2026 3:59:58 PM EST
155.88USD-1.167%(-1.84)94,254
After-hoursNov 18, 2026 4:00:30 PM EST
156.23USD+0.225%(+0.35)
Loading…
Loading…
Healthcare
Biotechnology
HQ
San Diego, CA, USA
Previous Close
$157.72
Beta
1.09
52-Week High
$200.00 2026-02-03
52-Week Low
$105.88 2025-11-20
SMA 50
$159.56
SMA 200
$160.00
Avg. Vol 10D
217,207
Avg. Vol 30D
175,262
Avg. Vol 90D
179,303
Relative Vol
0.54
19.53M
0.4800%
3,921
BLTE Profile

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.

BLTE Performance
PeriodPriceDateChangeBeta
1W155.942026-11-11-0.04%2.838
1M147.342026-10-19+5.80%1.086
3M162.572026-08-18-4.12%1.170
6M142.902026-05-18+9.08%1.002
1Y123.192025-11-18+26.54%1.093
2Y82.762024-11-18+88.35%—
5Y10.592022-04-29+1371.95%0.304
BLTE Stock Summary

Belite Bio, Inc (NASDAQ:BLTE) stock price today is $155.88, and today's volume is 94,254. BLTE is down 1.167% today. The 30 day average volume is 175,262. BLTE market cap is $6.28B with 40.27M shares outstanding.